Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. More Details
No risks detected for MYGN from our risk checks.
Fair value with moderate growth potential.
Share Price & News
How has Myriad Genetics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MYGN has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: MYGN underperformed the US Biotechs industry which returned 25% over the past year.
Return vs Market: MYGN underperformed the US Market which returned 12% over the past year.
Price Volatility Vs. Market
How volatile is Myriad Genetics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall StHow Much Are Myriad Genetics, Inc. (NASDAQ:MYGN) Insiders Spending On Buying Shares?
7 months ago | Simply Wall StOne Thing To Remember About The Myriad Genetics, Inc. (NASDAQ:MYGN) Share Price
7 months ago | Simply Wall StMyriad Genetics (NASDAQ:MYGN) Is Making Moderate Use Of Debt
Is Myriad Genetics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MYGN ($13.07) is trading below our estimate of fair value ($16.51)
Significantly Below Fair Value: MYGN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MYGN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: MYGN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MYGN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MYGN is good value based on its PB Ratio (1.1x) compared to the US Biotechs industry average (3.3x).
How is Myriad Genetics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MYGN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: MYGN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MYGN's is expected to become profitable in the next 3 years.
Revenue vs Market: MYGN's revenue (7% per year) is forecast to grow slower than the US market (10% per year).
High Growth Revenue: MYGN's revenue (7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MYGN's Return on Equity is forecast to be low in 3 years time (6.8%).
How has Myriad Genetics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MYGN is currently unprofitable.
Growing Profit Margin: MYGN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MYGN is unprofitable, and losses have increased over the past 5 years at a rate of 50% per year.
Accelerating Growth: Unable to compare MYGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MYGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12.8%).
Return on Equity
High ROE: MYGN has a negative Return on Equity (-21.74%), as it is currently unprofitable.
How is Myriad Genetics's financial position?
Financial Position Analysis
Short Term Liabilities: MYGN's short term assets ($331.7M) exceed its short term liabilities ($147.0M).
Long Term Liabilities: MYGN's short term assets ($331.7M) do not cover its long term liabilities ($339.4M).
Debt to Equity History and Analysis
Debt Level: MYGN's debt to equity ratio (24.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if MYGN's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: MYGN's debt is well covered by operating cash flow (27%).
Interest Coverage: Insufficient data to determine if MYGN's interest payments on its debt are well covered by EBIT.
What is Myriad Genetics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MYGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MYGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MYGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MYGN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MYGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Paul Diaz (58 yo)
Mr. Paul J. Diaz has been the Chief Executive Officer, President and Director of Myriad Genetics, Inc. since August 13, 2020. He served as a Partner at Cressey & Company LP since September 2017. Since Augu ...
|Executive VP||6yrs||US$4.20m||0.12% |
|Chief Scientific Officer||10.58yrs||US$1.83m||0.19% |
|Group President of Myriad Oncology||1.5yrs||US$1.70m||0.14% |
|CEO, President & Director||0.17yr||no data||no data|
|Senior Vice President of Investor Relations||no data||no data||no data|
|Executive VP||1.25yrs||no data||0.12% |
|Chief Compliance Officer||1.75yrs||no data||no data|
|Executive Vice President of Human Resources||9.42yrs||no data||0.089% |
|Executive Vice President of Reimbursement Strategy||4.08yrs||no data||0.12% |
|President of Myriad Neuroscience & Myriad Autoimmune||3.17yrs||no data||0.19% |
|Chief Medical Officer||0.75yr||no data||no data|
|Senior Vice President of Medical Affairs for Myriad Oncology||0.58yr||no data||no data|
Experienced Management: MYGN's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
|CEO, President & Director||0.17yr||no data||no data|
|Independent Director||0.42yr||US$309.19k||no data|
|Independent Director||11.08yrs||US$379.51k||0.065% |
|Independent Vice Chairman||no data||US$371.26k||0.056% |
|Independent Director||16.42yrs||US$458.19k||0.088% |
|Independent Director||16.42yrs||US$388.44k||0.050% |
|Independent Director||1.08yrs||US$370.26k||no data|
|Independent Director||0.25yr||no data||no data|
|Independent Director||1.08yrs||US$373.32k||no data|
|Independent Director||10.33yrs||US$384.38k||0.057% |
|Independent Chair of the Board||0.58yr||US$403.02k||0.044% |
|Independent Director||0.083yr||no data||no data|
Experienced Board: MYGN's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MYGN insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Myriad Genetics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Myriad Genetics, Inc.
- Ticker: MYGN
- Exchange: NasdaqGS
- Founded: 1991
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$982.954m
- Shares outstanding: 75.21m
- Website: https://myriad.com
Number of Employees
- Myriad Genetics, Inc.
- 320 Wakara Way
- Salt Lake City
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MYGN||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Oct 1995|
|MYD||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Oct 1995|
|MYD||XTRA (XETRA Trading Platform)||Yes||Common Stock||DE||EUR||Oct 1995|
|0K3W||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Oct 1995|
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hered ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/30 03:59|
|End of Day Share Price||2020/10/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.